A micro-epidemiological analysis of febrile malaria in Coastal Kenya showing hotspots within hotspots
Abstract
Malaria transmission is spatially heterogeneous. This reduces the efficacy of control strategies, but focusing control strategies on clusters or 'hotspots' of transmission may be highly effective. Among 1,500 homesteads in coastal Kenya we calculated a) the fraction of febrile children with positive malaria smears per homestead, and b) the mean age of children with malaria per homestead. These two measures were inversely correlated, indicating that children in homesteads at higher transmission acquire immunity more rapidly. This inverse correlation increased gradually with increasing spatial scale of analysis, and hotspots of febrile malaria were identified at every scale. We found hotspots within hotspots, down to the level of an individual homestead. Febrile malaria hotspots were temporally unstable, but 4km radius hotspots could be targeted for one month following one month periods of surveillance.
Article and author information
Author details
Reviewing Editor
- Mercedes Pascual, University of Michigan, United States
Ethics
Human subjects: Informed consent for participation was obtained, and specific ethical approval was obtained from the KEMRI Ethical Review Committee (SSC Protocol No. 2413: Spatial Epidemiology of Malaria Cases in the Kilifi District Demographic Surveillance Area). The KEMRI ethical review committee required that participants consent for participation in research and for their data to be stored, but does not require a further explicit statement consenting to publication. Our institutional guidelines would require this only in the event that individuals were identifiable in the publication.
Version history
- Received: December 19, 2013
- Accepted: April 1, 2014
- Accepted Manuscript published: April 24, 2014 (version 1)
- Version of Record published: April 29, 2014 (version 2)
Copyright
© 2014, Bejon et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,413
- Page views
-
- 295
- Downloads
-
- 101
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Epidemiology and Global Health
- Microbiology and Infectious Disease
eLife has published papers on many tropical diseases, including malaria, Ebola, leishmaniases, Dengue and African sleeping sickness.
-
- Epidemiology and Global Health
Paxlovid, a SARS-CoV-2 antiviral, not only prevents severe illness but also curtails viral shedding, lowering transmission risks from treated patients. By fitting a mathematical model of within-host Omicron viral dynamics to electronic health records data from 208 hospitalized patients in Hong Kong, we estimate that Paxlovid can inhibit over 90% of viral replication. However, its effectiveness critically depends on the timing of treatment. If treatment is initiated three days after symptoms first appear, we estimate a 17% chance of a post-treatment viral rebound and a 12% (95% CI: 0%-16%) reduction in overall infectiousness for non-rebound cases. Earlier treatment significantly elevates the risk of rebound without further reducing infectiousness, whereas starting beyond five days reduces its efficacy in curbing peak viral shedding. Among the 104 patients who received Paxlovid, 62% began treatment within an optimal three-to-five-day day window after symptoms appeared. Our findings indicate that broader global access to Paxlovid, coupled with appropriately timed treatment, can mitigate the severity and transmission of SARS-Cov-2.